The October 28 data readout is the key near-term catalyst for CHRS. Investors should watch for efficacy and safety signals in the tagmokitug-toripalimab combination across multiple solid tumor types, which could significantly affect the stock depending on results.
Price Chart
Executive Summary
Coherus Oncology announced it will release interim clinical data for tagmokitug (anti-CCR8 antibody) combined with toripalimab in multiple solid tumors on October 28, 2026, followed by a management webcast. The event is a data readout catalyst for a mid-stage pipeline candidate, but no actual results are disclosed yet.
Key Facts
- Interim clinical data for tagmokitug (cytolytic CCR8 antibody) with toripalimab will be released on October 28, 2026.
- Management webcast scheduled from 4:30 p.m. to 6:00 p.m. EDT on the same day.
- Tagmokitug is in Phase 1b/2a studies for advanced solid tumors including head and neck, colorectal, gastric, GEJ, esophageal adenocarcinoma, and esophageal squamous cell carcinoma.
- No financial figures, guidance, or regulatory decisions are included in this press release.
Financial Impact
No financial data disclosed; impact depends on interim data results.
Risk Factors
- Interim data may be inconclusive or show limited efficacy, leading to negative market reaction.
- Tagmokitug is an early-stage asset; clinical failure would remove a key pipeline value driver.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3381161 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 13d ago | Press Release | $1.07 | awaiting T+60 | — | $1.07 (+0.00%) |
Aug 17, 2026 10w ago | Press Release | $1.34 | awaiting T+60 | — | $1.07 (−20.15%) |
Jul 22, 2026 13w ago | Press Release | $1.43 $1.07 | ▼ −25.17% | ▼ −28.44% | $1.07 (−25.17%) |
Jun 15, 2026 19w ago | 8-K | $1.38 $1.34 | ▼ −2.90% | ▼ −3.90% | $1.07 (−22.46%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.40 $1.37 | ▲ +2.14% | ▲ +5.41% | $1.07 (+23.57%) |
May 28, 2026 21w ago | DEFA14A | $1.65 $1.42 | ▼ −13.94% | ▼ −15.67% | $1.07 (−35.15%) |
May 11, 2026 24w ago | Press Release | $1.71 $1.27 | ▼ −26.02% | ▼ −30.41% | $1.07 (−37.43%) |
May 5, 2026 25w ago | DEFA14A | $1.75 $1.41 | ▼ −19.43% | ▼ −21.49% | $1.07 (−38.86%) |
May 4, 2026 25w ago | Press Release | $1.73 $1.41 | ▼ −18.50% | ▼ −20.35% | $1.07 (−38.15%) |
Mar 9, 2026 33w ago | Press Release | $1.95 $1.47 | ▼ −24.62% | ▼ −36.30% | $1.07 (−45.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers